Tailored Intervention to Improve Patient Adherence to Secondary Stroke Prevention Medication

January 19, 2015 updated by: Ulla Hedegaard, Odense University Hospital

Pharmacist Intervention Programme to Improve Medication Adherence in Stroke Patients

Patient suffering a Transient Ischemic Attack (TIA) or stroke are subsequently at high risk of a new stroke, however, poor adherence to secondary prevention medications occurs frequently within this patient group. The purpose of this study is to evaluate whether a complex tailored pharmacist intervention will lead to increased adherence to secondary stroke prevention medications and less new stroke events when compared to a usual care group. Interventions focus on motivational interviewing, medication review and telephone follow up.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

211

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Odense C, Denmark, 5000
        • Odense University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age: 18 years or older
  • Patient admitted or receiving ambulatory treatment for an acute transient ischemic attack or ischemic stroke which has occurred within the previous 30 days.
  • The patient or a carer usually dispenses the patient's medications
  • Written consent

Exclusion Criteria:

  • Cognitive or physical impairment that would preclude comprehension of a conversation
  • Terminal illness
  • Lives in a care home or an institution
  • Receives dose dispensed medicine from a pharmacy
  • Medicine is dispensed by a nurse in the patient's home
  • Correctional mental health patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Usual care
Behavioral: Usual care
Experimental: Complex tailored intervention

The intervention consists of 3 elements:

  1. Medication review with recommendations focused on antithrombotics and adherence to guidelines and patient´s adherence to medications.
  2. Discharge consultation with an pharmacist using motivational interviewing techniques.
  3. Follow-up telephone calls one week, two months and six months after discharge.
Behavioral: Usual care
Behavioral: Complex tailored intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Medication Adherence to antiplatelets, anticoagulants and statins measured by proportion of days covered (PDC).
Time Frame: One year from inclusion
One year from inclusion
For antiplatelets, anticoagulants and statins: Percent of patients that are at least 80% adherent (PDC>0.8)
Time Frame: 1 year from inclusion
1 year from inclusion

Secondary Outcome Measures

Outcome Measure
Time Frame
Medication Adherence to antihypertensives measured by proportion of days covered (PDC)
Time Frame: One year from inclusion
One year from inclusion
Percent of patients that are at least 80% adherent (PDC>0.8) to antihypertensives
Time Frame: One year from inclusion
One year from inclusion
Non-persistence with thromboprophylactic agents ( antiplatelets, anticoagulants, statins and antihypertensives) measured by percent of patients that are not supplied with medication for more than 3 continuous months
Time Frame: One year from inclusion
One year from inclusion
Accept rate for thromboprophylactic agents measured by percent of patients starting treatment within 0-90 days after discharge.
Time Frame: 3 months from discharge
3 months from discharge
Composite endpoint: stroke, myocardial infarction or cardiovascular death
Time Frame: One year from inclusion
One year from inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Odense University Hospital

Collaborators

University of Southern Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Actual)

February 1, 2013

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

September 10, 2012

First Submitted That Met QC Criteria

September 10, 2012

First Posted (Estimate)

September 12, 2012

Study Record Updates

Last Update Posted (Estimate)

January 21, 2015

Last Update Submitted That Met QC Criteria

January 19, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AKF-381

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Usual care

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe